Cipatinib Tosylate

托西酸西帕替尼

Report date: 2023/06/28 17:07:39
NME

Base Information

Drug NameCipatinib Tosylate
Drug Alias NameSipatinib TosylateSHR-1086
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnti-HER2EGFR T790M inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2EGFR T790M
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A